Under a tenth of people that would benefit from obesity jabs like Wegovy are able to get them, states the WHO as it publishes its initial guidance on the therapies.
Given over a billion individuals worldwide currently classified as obese, it is advocating for increased and just access to this class of drugs.
Based on forecasts, over two billion could be obese by 2030 without intervention.
"The latest guidelines affirms that obesity is a long-term condition that can be addressed with thorough and ongoing care," said the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and supply-chain constraints are significant obstacles to universal access to the treatments that can assist patients in reducing considerable body mass, notes the agency.
Skinny Jab Scarcity
Even under the current most optimistic outlook, the production of GLP-1 therapies might only reach around 100 million people – fewer than 10% of those who need them, per the health organization.
The advice calls on countries and companies to increase access, by strategies like patent sharing.
A patent on semaglutide – the main component of the drug Wegovy – is set to lapse in a number of nations in 2026.
How Obesity Injections Work
These medications replicate a biological compound to reduce digestion speed, curb appetite and increase the sense of being full so individuals consume fewer calories.
Individuals commonly see weight reduction in the initial weeks of commencing the weekly injections.
Studies indicates patients may put most of the weight back on a year later of halting the treatment, when their normal food cravings come back.
To be overweight or obese elevates your likelihood for experiencing medical conditions, including diabetes, heart disease, brain attack, and specific cancers.
Obesity impacts individuals in all nations and was responsible for over three and a half million fatalities worldwide in 2024, per the health agency.
